Previous treatment with brentuximab vedotin.
Previously received an allogeneic transplant.
Patients with current diagnosis of primary cutaneous ALCL (patients whose ALCL has transformed to sALCL are eligible).
Known cerebral/meningeal disease including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
Female patients who are lactating and breastfeeding or pregnant
Known human immunodeficiency virus (HIV) positive
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection

NCT01909934_exc_T1
Drug
brentuximab
NCT01909934_exc_T2
Procedure
allogeneic transplant
NCT01909934_exc_T3
Condition
primary cutaneous ALCL
NCT01909934_exc_T4
Condition
sALCL
NCT01909934_exc_T5
Condition
meningeal disease
NCT01909934_exc_T6
Condition
ebral/me ease in
NCT01909934_exc_T7
Condition
progressive multifocal leukoencephalopathy
NCT01909934_exc_T8
Condition
PML
NCT01909934_exc_T9
Scope
cerebral/meningeal disease
NCT01909934_exc_T11
Measurement
human immunodeficiency virus
NCT01909934_exc_T12
Measurement
HIV
NCT01909934_exc_T13
Value
positive
NCT01909934_exc_T14
Measurement
hepatitis B surface antigen
NCT01909934_exc_T15
Value
positive
NCT01909934_exc_T16
Condition
hepatitis C infection
NCT01909934_exc_T17
Qualifier
active